Scopolamine in Healthy Volunteers

The investigational product is a combination product comprised of: (a) a vial prefilled with
DPI-386 Nasal Gel, and (b) a nasal gel pump attached to the vial during the manufacturing
process. For Cohorts 1 through 4, 9 through 10, and 13 each 0.12 gram of the gel contains 0.2
mg of scopolamine HBr as the active ingredient along with the excipients sodium citrate,
citric acid, sodium metabisulfite, glycerin, benzalkonium chloride, polyvinyl alcohol and
purified water. For Cohorts 1 through 4, 9, 10 and 13 each vial of DPI-386 Nasal Gel is a
multi-dose product, sufficient for six individual doses. Each pumping action is designed to
deliver a single 0.12 g dose. The DPI-386 Nasal Gel for Cohorts 1 through 4 and 13 is
formulated to contain 0.2 mg scopolamine HBr per 0.12 g dose, with each dose therefore
described as "0.2 mg / 0.12 g". For Cohort 6 the dose is "0.8 mg / 0.12 g", and for cohort 7
the dose is "1.0 mg / 0.12 g", and for Cohort 8 the dose is "1.2 mg / 0.12 g", and for Cohort
11 the dose is "0.4 mg / 0.12 g", and for Cohort 12 the dose is "0.6 mg / 0.12 g", delivered
in a single dose.

Each vial/pump unit must be primed by research staff prior to first dose delivery. Subjects
will self-administer the drug under guidance from the study staff.

Inclusion Criteria:

1. Provision of signed and dated ICF.

2. Stated willingness to comply with all study procedures and availability for the
duration of the study.

3. Male or female, aged 18 to 40 (inclusive).

4. Males and females must agree to use highly effective contraception (e.g. double
barrier method) for 4 weeks after receiving the last dose of treatment.

5. Have a body mass index (BMI) within a range of 18 to 30 inclusive.

6. In good general health as evidenced by medical history with no recent history or
current diagnosis of significant cardiovascular or respiratory problems as assessed by
the PI or qualified designee.

7. Hematology, biochemistry, urinalysis and drug and alcohol laboratory test results that
are determined by the PI or qualified designee to be not clinically significant.

8. Ability to take intranasal medication (for Cohorts 1-4, and 6-12 only) and willingness
to adhere to the study schedule and time constraints.

9. For females of child-bearing potential: willingness to provide a sample for the
pregnancy test upon every visit. Test must be negative.

Note: Women of non-childbearing potential are defined as those who are non-surgically
sterile (i.e., without menses for at least 12 consecutive months) or surgically
sterile (i.e., those who underwent a hysterectomy with or without oophorectomy,
fallopian tube ligation, and endometrial ablation).

10. Agreement to adhere to the following lifestyle compliance considerations:

1. Refrain from consumption of grapefruit and any substance containing grapefruit
for seven days prior to, during, and for seven days after the treatment day.

2. Caffeine intake limited to 300 mg on treatment day (two 8-ounce cups).

3. Abstain from alcohol for 24 hours prior to first dose of study medication.

4. Refrain from any type of nicotine within 30 days prior to the screening visit and
through the completion of the treatment day.

Exclusion Criteria:

1. Pregnancy, lactation, or positive serum pregnancy test at screening.

2. Known allergic reactions to scopolamine or other anticholinergics.

3. Currently prescribed any of the following medication types and used within the
specified washout periods below:

- belladonna alkaloids (washout 2 weeks),

- antihistamines (including meclizine) (washout 2 weeks),

- tricyclic antidepressants (washout 2 weeks),

- muscle relaxants (washout 4 days) and

- nasal decongestants (washout 4 days) (for Cohorts 1-4, and 6-12 only).

4. Hospitalization or significant surgery requiring hospital admittance within the past
six months.

5. Treatment with another investigational drug or other intervention within the past 30
days.

6. Having donated blood or plasma or suffered significant blood loss within the past 30
days.

7. Use of nicotine within 30 days prior to the screening visit.

8. Having any of the following medical conditions within the last two years or if any of
the following medical conditions were experienced more than two years ago and are
deemed clinically significant by the PI or qualified designee:

1. Significant gastrointestinal disorder, asthma, or seizure disorders.

2. History of narrow-angle glaucoma.

3. History of urinary retention or clinically significant symptomatic benign
prostatic hypertrophy (BPH).

4. History of moderate or severe substance use disorder.

5. Nasal, nasal sinus, or nasal mucosa surgery (for Cohorts 1-4, and 6-12 only).